

Luigi Nezi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4631616/publications.pdf>

Version: 2024-02-01

39
papers

10,877
citations

218381

26
h-index

377514

34
g-index

41
all docs

41
docs citations

41
times ranked

20031
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	6.0	3,126
2	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
3	DNA breaks and chromosome pulverization from errors in mitosis. <i>Nature</i> , 2012, 482, 53-58.	13.7	1,051
4	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , 2014, 514, 628-632.	13.7	998
5	The Mad1/Mad2 Complex as a Template for Mad2 Activation in the Spindle Assembly Checkpoint. <i>Current Biology</i> , 2005, 15, 214-225.	1.8	376
6	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	6.0	369
7	Passenger deletions generate therapeutic vulnerabilities in cancer. <i>Nature</i> , 2012, 488, 337-342.	13.7	294
8	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
9	Reporting guidelines for human microbiome research: the STORMS checklist. <i>Nature Medicine</i> , 2021, 27, 1885-1892.	15.2	170
10	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	15.2	158
11	Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	142
12	Sister chromatid tension and the spindle assembly checkpoint. <i>Current Opinion in Cell Biology</i> , 2009, 21, 785-795.	2.6	137
13	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414.	13.7	129
14	Determinants of conformational dimerization of Mad2 and its inhibition by p31comet. <i>EMBO Journal</i> , 2006, 25, 1273-1284.	3.5	124
15	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
16	In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 133-147.	2.9	114
17	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. <i>Cancer Cell</i> , 2017, 32, 88-100.e6.	7.7	114
18	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , 2017, 542, 362-366.	13.7	105

#	ARTICLE	IF	CITATIONS
19	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. <i>Cancer Cell</i> , 2015, 27, 644-657.	7.7	85
20	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 1091-1101.	0.4	68
21	Protein-tyrosine Phosphatase PTPD1 Regulates Focal Adhesion Kinase Autophosphorylation and Cell Migration. <i>Journal of Biological Chemistry</i> , 2008, 283, 10919-10929.	1.6	64
22	Extra-mitochondrial localisation of frataxin and its association with IscU1 during enterocyte-like differentiation of the human colon adenocarcinoma cell line Caco-2. <i>Journal of Cell Science</i> , 2005, 118, 3917-3924.	1.2	61
23	Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1296-305.	3.3	59
24	Accumulation of Mad2â€“Cdc20 complex during spindle checkpoint activation requires binding of open and closed conformers of Mad2 in <i>Saccharomyces cerevisiae</i> . <i>Journal of Cell Biology</i> , 2006, 174, 39-51.	2.3	51
25	Fecal Microbiota Transplantation Controls Murine Chronic Intestinal Inflammation by Modulating Immune Cell Functions and Gut Microbiota Composition. <i>Cells</i> , 2019, 8, 517.	1.8	50
26	PAF promotes stemness and radioresistance of glioma stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9086-E9095.	3.3	40
27	Role of the Mad2 Dimerization Interface in the Spindle Assembly Checkpoint Independent of Kinetochores. <i>Current Biology</i> , 2012, 22, 1900-1908.	1.8	26
28	TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103288.	2.0	20
29	Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome. <i>Journal of Clinical Oncology</i> , 2019, 37, 439-439.	0.8	16
30	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. <i>Genome Medicine</i> , 2020, 12, 94.	3.6	11
31	The Role of Proteases in Fibronectin Matrix Remodeling in Thyroid Epithelial Cell Monolayer Cultures. <i>Biological Chemistry</i> , 2002, 383, 167-76.	1.2	7
32	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i> -mutated melanoma. <i>Oncolmmunology</i> , 2021, 10, 1992880.	2.1	7
33	Characterization of DIP1, a novel nuclear protein in <i>Drosophila melanogaster</i> . <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 224-228.	1.0	4
34	1072P Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome. <i>Annals of Oncology</i> , 2021, 32, S889-S890.	0.6	1
35	1147P Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in locally advanced or oligometastatic melanoma: Preliminary results. <i>Annals of Oncology</i> , 2020, 31, S765-S766.	0.6	0
36	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. <i>Blood</i> , 2014, 124, 30-30.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Abstract 976: Metabolic eradication of treatment resistant cancer stem cells in pancreatic tumors: A clonal tracking-based platform for identifying the best personalized treatment. , 2015, , .		0
38	Abstract 1701: Identification of epigenetic modifiers able to suppress growth of pancreatic ductal adenocarcinoma: A patient-oriented in vivo functional platform. , 2015, , .		0
39	ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. Blood, 2016, 128, 359-359.	0.6	0